Rapport Therapeutics

At the Cantor conference, Rapport Therapeutics highlighted the differentiating platform around RAP-219 and pointed to strong phase II data in focal seizures (77.8% reduction, 24% seizure freedom). The company expects phase II data in October for bipolar mania and is already conducting two phase III studies in focal seizures, with active patient recruitment and a partnership for China. A long-acting injectable (LAI) formulation of RAP-219 could double the market opportunity in epilepsy and extend patent protection to 2046/2047. Rapport reported roughly $430 million in cash at the end of Q2, sufficient through the second half of 2029, but continues to see clinical and regulatory risks. » Mais em de.investing.com

Rapport Therapeutics shares rose to a new all-time high of $44.38 and are up about 190% year to date; the six-month performance is 57%. With a market capitalization of roughly $2.03 billion, an InvestingPro analysis classifies the stock as overvalued, and analysts do not expect profitability this year. Several firms initiated or confirmed positive ratings and price targets (including William Blair $79.03, Leerink $52.00, Citizens $80.00, Truist $56.00, Stifel $56.00); phase-2 results for RAP-219 in bipolar mania are expected in Q4 2026. » Mais em de.investing.com

Shares of Rapport Therapeutics rose to a record high of $44.28, giving a gain of about 177.11% over the past year. Market capitalization is roughly $2 billion, while earnings per share for the last twelve months are -$2.56. Analyst ratings vary: William Blair (outperform, fair value $79.03), Leerink (outperform, $52), Truist (buy, target $56), Stifel (buy, $56) and Citizens (market outperform, $80). InvestingPro classifies the stock as overvalued; quarterly results are expected in nine days. » Mais em de.investing.com